Silymarin/silybin regulates a significant number of these lipid metabolic genes, including iPLA2/PLA2G6, ATGL/PNPLA2, PLD1, LPIN2, and by trend PNPLA3 (which is a major genetic risk factor for MAFLD 131) and HSD17B13, counteracting the observed dysregulation in liver diseases. This evidence concerns the gene PNPLA2 and liver disorder.